🌿Wellness Wednesday: Peptides Part 3 There is a LOT of discussion right now around Retatrutide — and not just because of the remarkable weight loss data. Retatrutide is a triple agonist, meaning it targets: * GLP-1 * GIP * Glucagon receptors In early trials, it has shown weight loss approaching bariatric surgery levels in some patients. But behind the scenes, there is another major battle happening: How should Retatrutide be classified? Eli Lilly and Company has been arguing that Retatrutide should potentially be classified as a biologic rather than a traditional peptide drug. Why does that matter? Because biologics are regulated differently than standard drugs: * Longer exclusivity protections * Different manufacturing standards * More restrictions on compounding * Greater barriers to generic or copycat competition In simple terms: If Retatrutide ultimately receives biologic-type protection, it could significantly limit future compounding and keep costs very high for pat...